Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan 15;52(2):228-34.
doi: 10.1093/cid/ciq113.

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians

Theodoros Kelesidis  1 , Romney Humphries, Daniel Z Uslan, David A Pegues
Affiliations

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians

Theodoros Kelesidis et al. Clin Infect Dis. .

Abstract

Daptomycin is the only antibiotic with in vitro bactericidal activity against vancomycin-resistant Enterococcus (VRE) that is approved by the Food and Drug Administration (FDA). Data on the potential emergence of daptomycin nonsusceptibility among enterococci remain limited. We systematically reviewed the published literature for reports of isolates of enterococci that were daptomycin nonsusceptible and assessed the clinical significance and outcome of therapy. Based on susceptibility breakpoints approved by the Clinical Laboratory Standards Institute (CLSI), daptomycin has in vitro activity against >90% of enterococcal isolates. Less than 2% of enterococcal isolates were daptomycin nonsusceptible, with minimum inhibitory concentrations (MICs) >4 μg/mL. The prevalence of nonsusceptibility of VRE isolates to daptomycin may be overestimated due to the spread of clonally related isolates in health care settings. Clinicians should be aware of the possibility of the emergence of daptomycin nonsusceptibility and should closely monitor daptomycin MICs of enterococci isolated during treatment.

PubMed Disclaimer

References

    1. Eliopoulos GM. Microbiology of drugs for treating multiply drug-resistant gram-positive bacteria. J Infect. 2009;59:S17–24. - PubMed
    1. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement. CLSI; 2010. pp. M100–S20. Available at http://www.clsi.org/source/orders/free/m100-s20-u.pdf .
    1. Package insert. Cubicin (daptomycin) Lexington, MA: Cubist Pharmaceuticals; 2007.
    1. Rathe M, Kristensen L, Ellermann-Eriksen S, Thomsen MK, Schumacher H. Vancomycin-resistant Enterococcus spp: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin. APMIS. 2010;118:66–73. - PubMed
    1. Sader HS, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008) Diagn Microbiol Infect Dis. 2009;65:158–62. - PubMed